Hetrombopag (SHR-8735) is a potent, selective, orally-active Thrombopoietin (TPO) receptor agonist.
Hetrombopag specifically stimulates proliferation and/or differentiation of human TPOR-expressing cells, including 32D-MPL and human hematopoietic stem cells, with low nanomolar EC50 values through stimulation of STAT, PI3K and ERK signalling pathways.
Hetrombopag specifically enhances the viability and promoted the growth of 32D-MPL cells in hollow fibres implanted in nude mice, exhibiting much higher potency than eltrombopag in vivo.
